BRCA1 functions as a novel transcriptional cofactor in HIV-1 infection by Irene Guendel et al.
Guendel et al. Virology Journal  (2015) 12:40 
DOI 10.1186/s12985-015-0266-8RESEARCH Open AccessBRCA1 functions as a novel transcriptional
cofactor in HIV-1 infection
Irene Guendel1, Beatrix W Meltzer1, Alan Baer1, Seth M Dever2,3, Kristoffer Valerie2, Jia Guo1, Yuntao Wu1
and Kylene Kehn-Hall1*Abstract
Background: Viruses have naturally evolved elegant strategies to manipulate the host’s cellular machinery,
including ways to hijack cellular DNA repair proteins to aid in their own replication. Retroviruses induce DNA
damage through integration of their genome into host DNA. DNA damage signaling proteins including ATR, ATM
and BRCA1 contribute to multiple steps in the HIV-1 life cycle, including integration and Vpr-induced G2/M arrest.
However, there have been no studies to date regarding the role of BRCA1 in HIV-1 transcription.
Methods: Here we performed various transcriptional analyses to assess the role of BRCA1 in HIV-1 transcription by
overexpression, selective depletion, and treatment with small molecule inhibitors. We examined association of Tat
and BRCA1 through in vitro binding assays, as well as BRCA1-LTR association by chromatin immunoprecipitation.
Results: BRCA1 was found to be important for viral transcription as cells that lack BRCA1 displayed severely reduced
HIV-1 Tat-dependent transcription, and gain or loss-of-function studies resulted in enhanced or decreased transcription.
Moreover, Tat was detected in complex with BRCA1 aa504-802. Small molecule inhibition of BRCA1 phosphorylation
effector kinases, ATR and ATM, decreased Tat-dependent transcription, whereas a Chk2 inhibitor showed no effect.
Furthermore, BRCA1 was found at the viral promoter and treatment with curcumin and ATM inhibitors decreased
BRCA1 LTR occupancy. Importantly, these findings were validated in a highly relevant model of HIV infection and are
indicative of BRCA1 phosphorylation affecting Tat-dependent transcription.
Conclusions: BRCA1 presence at the HIV-1 promoter highlights a novel function of the multifaceted protein in HIV-1
infection. The BRCA1 pathway or enzymes that phosphorylate BRCA1 could potentially be used as complementary
host-based treatment for combined antiretroviral therapy, as there are multiple potent ATM inhibitors in development
as chemotherapeutics.
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Human immunodeficiency virus type 1 (HIV-1) is the
etiological agent of the acquired immunodeficiency
syndrome (AIDS). Currently approved combined anti-
retroviral therapy (cART) rely primarily on viral-based
inhibitors, and present research efforts focus on find-
ing new non-essential host targets that can provide
viral inhibition without creating drug-resistance select-
ive pressure on the virus. Therefore understanding the* Correspondence: kkehnhal@gmu.edu
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better approaches to complement treatment and expand
therapy considerations for multiple co-infections or HIV-
associated malignancies.
The HIV-1 transactivator of transcription, Tat, is an
essential regulatory protein that modulates the viral
chromatin landscape and transcriptional activation by
association with the transactivation response RNA loop
region, TAR, present on the proviral 5′ region at the
transcriptional initiation site (nt +1 to +57) on the HIV-
1 long terminal repeat (LTR). The Tat/TAR complex is
able to recruit various critical host factors including
basal transcription factors TBP, TFIIB, TFIID, TFIIH,l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the pTEF-b complex (Cdk9/Cyclin T1) to the RNA poly-
merase II holoenzyme (RNAP II) that occupies the LTR
[2-7]. pTEF-b is a ubiquitous positive acting elongation
factor that actively phosphorylates the carboxyl-terminal
domain (CTD) of RNAP II, and has been shown to be a
critical cofactor for Tat activation of elongation [8-10].
Retroviruses induce DNA damage through integration
of their genome into the host DNA. DNA damage sig-
naling proteins including ATR, ATM and BRCA1, con-
tribute to multiple steps in the HIV-1 life cycle, including
integration and Vpr-induced G2/M arrest [11-14]. How-
ever, there have been no studies to date regarding the role
of BRCA1 in HIV-1 transcription. Largely characterized in
cancer, the breast cancer susceptibility gene, BRCA1, is a
tumor suppressor protein that has implications in pro-
cesses such as cell cycle, DNA repair, and transcription.
These functions are accomplished by BRCA1 interacting
with cellular transcription and host factors, in addition to
stern regulatory mechanisms [15,16]. BRCA1 was first im-
plicated in transcription when its C-terminus [amino acid
(aa) 1560–1863] fused to Gal4 was able to activate tran-
scription [17], with aa1760-1863 being the minimal
transactivation domain (TAD). Within this TAD are
two BRCA1 C-terminus (BRCT) motifs that are found in
a large family of proteins important for DNA damage re-
sponse, such as DNA ligase IV, p53BP1, and base excision
response scaffold protein XRCC1 [18]. Since then, numer-
ous other findings have served to strengthen the connec-
tion between transcription and BRCA1. For example,
BRCA1 is part of the RNAP II holoenzyme complex
[19-21]. BRCA1 also interacts with multiple cofactors and
transcription factors including CBP/p300, Sp1, STAT1, es-
trogen receptor and BRG1 [22,23]. Among the genes
found to be transactivated by BRCA1 are Mdm2, Bax,
p21/Waf1, p27/Kip1, and GADD45α [24-30]. Moreover,
BRCA1 has been shown to be in complex with pTEF-b,
and Cyclin T1 has been shown to be an essential factor
for BRCA1-dependent activation of RNAP II transcription
[31]. Additionally, BRCA1 was reported to interact with
the SWI/SNF catalytic core unit BRG1 [32]. In recent
years, it has been further linked to chromatin alterations
in cancer, including recruitment to sites of DNA repair, in-
dicating a direct function of BRCA1 in transcriptional
control through chromatin structure modulation [33-36].
Taking into account these findings and its well-
documented involvement in transcriptional regulation and
chromatin remodeling capabilities, we were interested in
determining whether BRCA1 participates in HIV-1 Tat-
dependent transcription. Here, we have demonstrated
BRCA1 enhancement of HIV-1 Tat-dependent tran-
scription through gain-of-function and loss-of-function
studies. Tat was detected in complex with BRCA1 at
aa504-802 through in vitro binding assays and co-immunoprecipitated with BRCA1. Additionally, inhib-
ition of the effector kinase ATM, but not Chk2, resulted
in transcriptional decrease by loss of BRCA1 from the
viral promoter. Therefore, targeting the host BRCA1
activation pathway can serve as an attractive strategy
for the development of novel host-based therapeutics
that target HIV-1 viral transcription.
Results and discussion
BRCA1 enhances HIV-1 Tat-dependent transcription
The molecular function of BRCA1 has been the subject
of intensive studies since it was cloned in 1994 [37]. Pri-
marily in cancer, it has been characterized as a multifa-
ceted tumor suppressor protein due to its role in cell
cycle progression, DNA repair and DNA damage re-
sponse processes, transcription, RNAi pathway regula-
tion, and apoptosis [23,38]. Limited studies have linked
BRCA1 to HIV-1. Initially, Zimmerman et al. [13]
showed BRCA1-H2AX foci formation was required for
Vpr-induced G2 arrest. Later, this same group further
elaborated on the role of BRCA1 in infection by showing
Vpr-induced ATR-dependent activation of BRCA1 at
serine substrate S1423 as a response to genotoxic stress,
suggesting a model for Vpr-induced apoptosis via tran-
scriptional regulation of the BRCA1 target gene,
GADD45α [11]. Around the same time, Coberley et al.
[12] demonstrated alterations of various genes contrib-
uting to cell cycle transition at the G2/M checkpoint
through a temporal genetic network study in mock or
R5-tropic HIV-1 infected primary macrophages. Specif-
ically, infection activated mediators of cell cycling at
different times during infection including BRCA1 (inter-
mediate), and GADD45α (late). Furthermore, BRCA1 may
function as a transcriptional coactivator or corepressor, a
function that varies depending on its ability to recruit both
the basal transcription machinery and proteins implicated
in chromatin remodeling [32,39]. Consequently, we were
interested in characterizing BRCA1 function in HIV-1
transcription.
First we started our functional transcription studies in
cells that have a null background for BRCA1 expression.
UWB1.289 cells are derived from ovarian cancer in a
germ line BRCA1 mutation carrier and lack expression
of BRCA1, while UWB1.289 + BRCA1 cells are a stable
UWB1.289 derivative cell line carrying a pcDNA3 plas-
mid coding for wild-type BRCA1 [40]. Here we co-
transfected both set of cells with HIV-1 LTR-Luc,
pcDNA or Tat, and Renilla reporter plasmid as a control
for transfection efficiency between cell lines. Based on
scored luciferase activity, results in Figure 1A indicate
that there is ~13-fold difference in Tat transactivation of
the HIV-1 LTR in cells expressing BRCA1 (lane 2, black
bar) when compared to the BRCA1 null cells (lane 2,
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Figure 1 HIV-1 Tat-dependent transcription is more efficient in cells containing BRCA1. A. UWB1.289 BRCA1 null and UWB1.289 + BRCA1 cells
and were co-transfected with pcDNA or pcTat, LTR-Luc, and CMV-Luc (Renilla) plasmid DNA. Dual-Glo luciferase assay was performed 48 hours later as
described by the manufacturer. Raw data was normalized to Renilla luciferase expression in both cell lines, fold changes were calculated against
pcDNA (−Tat) condition for each cell line. B. TZM-bl cells were co-transfected with pcDNA or pcTat, and BRCA1 (wild-type) plasmid DNA. Bright-Glo
luciferase assay was performed 48 hours pos-transfection as described by the manufacturer. Cells containing pcTat and pcDNA were used as baseline
value for Tat-dependent LTR activation. C. TZM-bl cells were co-transfected with pcDNA or pcTat, and BRCA1 4P (mutant) plasmid DNA (S1387A,
S1423A, S1457A, and S1524A). Bright-Glo luciferase assay was performed 48 hours post-transfection. Cells containing pcTat and pcDNA were used as
baseline value for Tat-dependent LTR activation. D. TZM-bl cells were co-transfected with pcTat or siRNA against GFP (control) and BRCA1. Bright-Glo
luciferase assay was performed 48 hours post-transfection (left panel). Cells containing pcTat and siGFP were used as baseline value for Tat-dependent
LTR activation. BRCA1 depletion was confirmed by qRT-PCR and western blot (middle panel and inset). Fold changes against siGFP were calculated
relative to Actin using the ΔΔCt method. CellTiter-Glo cell viability assay (right panel) was performed as described by the manufacturer and viability
normalized to cells transfected with siGFP. Transfection assays were performed in triplicate and data plotted represents averaged data of two
independent experiments. Error bars show the standard error of two averaged independent measurements. Viability assays were performed in
triplicate. Western blots were performed for two independent experiments. Double asterisk indicates statistically significant difference p≤ 0.01.
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grated proviral DNA. To this end, we co-transfected
pcDNA or Tat, and BRCA1 into TZM-bl cells followed
by measurement of the HIV-1 LTR activity through lucif-
erase assays. The TZM-bl cell line is a widely used re-
porter system for the study of Tat-dependent transcription
as it harbors the luciferase gene under the control of an
integrated HIV-1 5′ LTR. Results in Figure 1B show a sig-
nificant transcriptional enhancement (~60% increase)
when BRCA1 is overexpressed in comparison to pcDNA-
transfected cells (compare lanes 5 and 4). Importantly, we
did not observe any effects of BRCA1 overexpression in
the absence of Tat, suggesting a Tat-dependent effect
(lanes 2 and 3). Given that BRCA1 is activated by phos-
phorylation [23], which has also been noted to occur dur-
ing HIV-1 infection [11], we assessed the importance of
BRCA1 phosphorylation in the enhancement of HIV-1
transcription. To this end, we utilized a BRCA1 mutant
construct with amino acid substitutions for the ATR/
ATM target serine residues S1387A, S1423A, S1457A,
and S1524A (BRCA1 4P). Similarly, TZM-bl cells were
co-transfected with Tat or pcDNA, and BRCA1 4P for
48 hours, with subsequent Tat-dependent HIV-1 LTR-
driven luciferase expression quantification. Results in Fig-
ure 1C showed no transcriptional enhancement between
cells containing control DNA or BRCA1 4P (lanes 4
and 5), indicating that BRCA1 activation by phosphoryl-
ation is important for the enhancement of Tat dependent
LTR transcription. Likewise, we did not see any effects of
BRCA1 4P overexpression in our basal controls (lanes 2
and 3).
Based on these findings, we next wanted to examine
the functional consequences of BRCA1 selective deple-
tion in Tat-dependent transcription. To assess the effect
of BRCA1 knockdown in HIV-1 transcription, we first
screened various siRNAs against BRCA1 and selected
the one producing more effective depletion results (data
not shown). TZM-bl cells were co-transfected with Tat
and siRNA against BRCA1 or GFP as a non-specific
control, and luciferase assays were performed 48 hours
post-transfection. Results in Figure 1D show that lucifer-
ase activity was significantly reduced by ~49% in cells
transfected with siBRCA1 compared to cells transfected
with siGFP (compare lanes 4 and 5). As additional con-
trols, BRCA1 levels in these cells were assayed by qRT-
PCR and western blot. BRCA1 was successfully repressed
(~90%) at the transcriptional level (compare lanes 6 and
7) and protein levels were decreased by ~68% (inset west-
ern blot panel). To discard the possibility that the decrease
in Tat-dependent transcription was due to cytotoxic ef-
fects upon BRCA1 knockdown, we performed viability as-
says on these samples. No changes in cell viability were
observed between samples transfected with control siRNA
or BRCA1 siRNA (compare lanes 8 and 9), indicating thatthe transcriptional efficiency loss is specific to BRCA1
selective depletion. Collectively, these data support the
permissive role of BRCA1 for Tat-dependent HIV-1
transcription.
BRCA1 is in complex with Tat
Collectively, molecular studies have shown ~1,500 in-
teractions between HIV-1 and human host proteins
[41]. In terms of Tat, the most studied interaction is its
association with the pTEF-b Cyclin T1 subunit by
which it exerts Tat-dependent transcriptional activation
of the HIV-1 promoter [1]. Because of the fact that Tat
is known to be in complex with various transcription
factors and host transcriptional machinery, we were in-
terested in determining whether these proteins associ-
ate. To this end, GST-BRCA1 constructs spanning the
full length of the protein (Figure 2A) and GST-Tat were
utilized in a pull-down assay from Flag-Tat transfected
TZM-bl whole cell lysates. TZM-bl cells were chosen
as they express robust levels of BRCA1 (see Figure 1D),
and are our base cell line for our transcriptional assays.
Beads bound to GST protein (lane 2, panel B) were
used as a background control. Membranes were probed
with antibodies against Flag (top panel) and BRCA1
(bottom panel). Western blot results in Figure 2B indi-
cate that the only detectable association between the
GST-BRCA1 fragments and Flag-Tat occurs at the
aa504-802 region (lane 4, top panel), while GST-Tat in-
versely confirmed the BRCA1-Tat association observed
with full length endogenous BRCA1 present in the
TZM-bl lysate (lane 8, bottom panel). In addition, we
saw GST-Tat binding to the Flag-Tat present in the cell
lysate (lane 8, top panel), doubling as a positive binding
control given that Tat exists as a Zn2+- or Cd2+-linked
dimer [42]. To further corroborate this interaction,
whole cell extracts from Tat-transfected TZM-bl cells
were immunoprecipitated with BRCA1 or IgG and
western blotted with anti-BRCA1, Flag, and BRG1 anti-
bodies. Results in Figure 2C show that BRCA1-Tat
interaction was observed specifically with the BRCA1
immunoprecipitation and not with the IgG. Probing
against BRG1 was used as an immunoprecipitation con-
trol since it has been shown to be a BRCA1-binding
partner [32]. Collectively, these results indicate that
physical interaction of BRCA1-Tat is detectable at the
aa504-802 region of BRCA1, suggesting that these pro-
teins are associated and accordingly, supporting BRCA1
participation in Tat-dependent transcription.
BRCA1 status affects enhancement of Tat-dependent
transcription during infection with pseudotyped particles
To further discern the role of BRCA1 in Tat-dependent
transcription, we generated pseudotyped HIV-1 LTR-
driven reporter viral particles. Figure 3A shows the
BRCA1
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Figure 2 BRCA1 associates with Tat. A. Schematic of five GST-BRCA1 fragments spanning the whole length protein. B. TZM-bl cells were transfected
with Flag-Tat plasmid DNA for 48 hours. One milligram of whole cell protein extract was incubated with 1 μg GST-BRCA1 constructs overnight and
processed as described in the Methods section. Samples were analyzed by western blot (top panel WB: anti-Flag, bottom panel WB: anti-BRCA1). C. TZM-bl
cells were transfected with Flag-Tat plasmid DNA for 48 hours. One milligram of TZM-bl whole cell protein extract was immunoprecipitated with anti-
BRCA1 and anti-IgG antibodies and analyzed by western blot (top panel WB: anti-BRCA1, middle panel WB: anti-Flag, bottom panel WB: anti-BRG1). Western
blots are representative of two independent experiments.
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pNL-RRE-SA-Luc that was used to incorporate the lu-
ciferase reporter gene. To assay the impact of BRCA1
status in Tat-dependent transcription in a live infection,
we utilized the UWB1.289 and UWB1.289 + BRCA1
cells for their unique ability to provide clean contrasts
of BRCA1 expression. Cells were co-transfected with
pcTat and Renilla reporter 24 hours prior to infection.
Next, cells were infected and processed for luciferase
assays 24 hours post-infection to allow for sufficient
proviral integration and transcription to take place. Re-
sults in Figure 3B indicate that in vNL-Luc infected
cells, LTR activation was observed at a lower level in –
BRCA1 cells (lane 2, white bar) when compared to +
BRCA1 cells (lane2, black bar), which exhibited a ~8-
fold increase in LTR activity over its –BRCA1 counter-
part. No significant background activation was detected
in + Tat mock infected cells (lane 1). Collectively, these
findings support our initial assays performed in these
cells with a non-integrated HIV-LTR reporter plasmid
(Figure 1A), where we detected a more tolerant envir-
onment for Tat-dependent transcription to occur in the
presence of BRCA1. Moreover, these results provide
further support that the enhancement of transcription
by BRCA1 is Tat-dependent.
Given the importance of BRCA1 to the cell cycle and
the fact that HIV-1 transcription has been shown to be en-
hanced in the G2 phase of the cell cycle [11-13,23,43,44],
experiments were performed to determine if UWB1.289cells had a difference in cell cycle distribution. It has been
previously shown that UWB1.289 cells display no differ-
ence in cell cycle profile in the absence of stress, but when
cells were subjected to irradiation, a G2/M arrest was ob-
served with the BRCA1 complemented cells [40]. To de-
termine if any alterations in cell cycle were occurring in
the UWB1.289 and UWB1.289 + BRCA1 cells following
HIV infection, cell cycle analysis using propidium iodine
staining and flow cytometry was performed. No changes
in cell cycle distribution between these two cell derivatives
were observed (Figure 3C). As Sp1 is a well-known inter-
acting partner of BRCA1, the binding of Sp1 to the LTR in
the presence and absence of BRCA1 was assessed by chro-
matin immunoprecipitation. ChIP assays from vNL-Luc
infected –BRCA1 and + BRCA1 cells were performed
using antibodies against RNAP II (positive control), V5
(negative control) and Sp1. There was no significant
difference in Sp1 or RNAP II binding to the LTR be-
tween the two cell populations (Figure 3D), indicating
that differential binding of Sp1 to the LTR is not a contrib-
uting factor to the decreased LTR activation observed in
the –BRCA1 cells. Collectively, these results suggest that
BRCA1 plays a direct and critical role in Tat-dependent
HIV transcription independent of cell cycle effects.
Small molecule inhibition of BRCA1 gene expression
affects HIV-1 Tat-dependent transcription
Currently, there are no therapeutic agents specifically tar-




5’ LTR      IRES RRE Luciferase 3’ LTR









































































1                          2
Figure 3 BRCA1 status affects enhancement of Tat-dependent transcription during infection with pseudotyped particles. A. Schematic
depicting the LTR-driven reporter plasmid pNL-RRE-SA-Luc. B. UWB1.289 BRCA1 null and UWB1.289 + BRCA1 cells and were co-transfected with
pcTat and CMV-Luc (Renilla) plasmid DNA 24 hours prior to infection with LTR-driven reporter viral particles. Dual-Glo luciferase assay was
performed 24 hours post-infection as described by the manufacturer. Raw data was normalized to Renilla luciferase expression in both cell
lines, fold changes were calculated against + Tat mock infected cells (lane 1). Transfection and infection assays were performed in triplicate
and data plotted represents averaged data of two independent experiments. Single asterisk indicates p < 0.05. C. UWB1.289 BRCA1 null and
UWB1.289 + BRCA1 cells were infected with VSVG-pseudotyped NL4-3. Cells were collected 48 hours post-infection, stained with propidium
iodine, and analyzed by flow cytometry. Results are representative of three biological replicates. D. Cells were infected as described above and
collected at 48 hours post-infection for ChIP analysis. Antibodies used for ChIP were anti-RNA polymerase II (RNAP II, 10 μg), anti-Sp1 (10 μg),
and anti-V5 (10 μg). Quantitative PCR was performed using SYBR Green PCR Master Mix to analyze immunoprecipitated material.
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histone acetylation impairment at the BRCA1 promoter
[45]. Generally, curcumin is categorized as a multifactorial
compound characterized by tolerable doses linked to
antioxidant therapy, anti-tumor effects, and anti-viral
effects [45-50]. Moreover, curcumin has been shown to
suppress pathways concomitant to HIV-1 replication and
HIV-1 associated neurocognitive disorders (HAND); and
when administered as adjuvant therapy to existing cART,
curcumin has been shown to enhance the proteaseinhibitor indinavir antiretroviral activity in persistently in-
fected cells [51-54]. In addition, a recent study demon-
strated multi-pathway involvement in curcumin-induced
inhibition of Tat-dependent transcription [55]. Here, the
authors showed modulation of the HDAC1/NF-κB path-
way used by HIV-1 to exert chromatin remodeling at the
viral promoter and further promoter activation by NF-κB.
Despite curcumin not being BRCA1-specific, we were in-
terested in using the compound as a model for small mol-
ecule inhibition of BRCA1.
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based system, TZM-bl cells were treated for 24 hours
with vehicle (DMSO) or a titration of curcumin deter-
mined from concentrations used in the literature (0.5, 1,
10, and 20 μM). Western blot was then performed using
anti-BRCA1 and anti-β-actin antibodies to determine
the expression levels of BRCA1. Results in Figure 4A show
a dose-dependent loss of BRCA1 expression with curcu-
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Figure 4 Curcumin decreases BRCA1 occupancy at the HIV-1 LTR. A. TZ
vehicle (DMSO) or a titration of curcumin (0.5, 1, 10, and 20 μM). Samples wer
protein abundance versus curcumin treatment based on the average den
independent measurements. Western blot is representative of three inde
independent treatments to acquire a dose–response curve of BRCA1 expressi
treated the next day with DMSO or 20 μM curcumin. Bright-Glo luciferase ass
treatment as described by the manufacturer. Data was normalized to cells co
activation. Transfection and treatment assays were performed in triplicate and
Error bars show the standard error of two averaged independent measureme
transfected with pcTat and treated the next day with DMSO or curcumin (20
used for ChIP were anti-BRCA1 (10 μg), anti-IgG (10 μg), and anti-RNA polyme
PCR Master Mix to analyze immunoprecipitated material. Single asterisk indica
difference p≤ 0.01.1 to 2–5). Next, we confirmed Tat-dependent transcrip-
tion inhibition by treating Tat-transfected TZM-bl cells
with 20 μM of curcumin. Results in Figure 4B show a sig-
nificant decrease in transcription (~46%) with curcumin
when compared to DMSO (compare lanes 3 and 4) that is
specific to treatment and not due to compound cytotox-
icity (compare lanes 5 and 6) and likens previously pub-
lished data [55]. We next sought to determine if BRCA1
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transfected DMSO- or curcumin-treated (20 μM) TZM-bl
cells were performed using antibodies against RNAP II
(positive control), IgG (negative control) and BRCA1.
Interestingly, we observed the presence of BRCA1 at the
viral promoter (Figure 4C). To our best knowledge, this is
the first instance that BRCA1 has been detected at the
HIV-1 LTR. Conversely curcumin treatment resulted in a
significant ~2.9-fold loss of BRCA1 occupancy from the
activated HIV-1 LTR when compared to the DMSO con-
trol (lane 3). Collectively, these results are suggestive of
BRCA1 playing a role in HIV-1 Tat dependent transcrip-
tion, and implies the use of chemotherapeutic agents
treating BRCA1 as a druggable target.
Inhibition of upstream BRCA1 phosphorylation effectors,
ATR/ATM, decreases Tat-dependent transcription
BRCA1 contains a serine cluster domain (SCD) spanning
aa1280-1524, a common motif present in ATR/ATM pro-
tein targets [56]. ATR phosphorylates BRCA1 on serine
1423 in response to UV damage or HU-induced replica-
tion arrest [57], while ATM-mediated phosphorylation
events at serines 1387, 1423, 1457 and 1524, have been
characterized in response to ionizing radiation-induced
damage [58,59]. While the Chk2 phosphorylation site is
not located within the SCD region, its phosphorylation of
serine 988 occurs in response to the same stressors as with
ATM [60]. Because cellular stress was shown to be highly
conducive to HIV-1 replication [61], we next looked at the
effect of ATR/ATM inhibition on Tat-dependent HIV-1
transcription. TZM-bl cells were transfected with Tat and
treated the next day with vehicle or a titration of caffeine.
Caffeine is a methylxanthine that has been used exten-
sively to study ATR/ATM signaling as a natural inhibitor
of these kinases [62]. Forty eight hours post-treatment the
cells were subjected to luciferase assays. As can be ob-
served in Figure 5A, there is a dose-dependent decrease in
HIV-1 transcription with increasing concentrations of caf-
feine of up to ~88% inhibition when compared to vehicle
(compare lane 2 to 3–5). To confirm compound inhibition
specificity, we performed cell viability assays of treated
cells to measure inhibitor-induced cell death. Results in
Figure 5B show that caffeine was not toxic at 500 μM or
2 mM. Working concentrations in published literature use
caffeine up to 10 mM, however we observed that in our
system, 5 mM caffeine decreased cell viability by ~60%
(lane 5). Thus, treatment with 2 mM caffeine results in a
viable ~60% Tat-dependent transcriptional activity de-
crease without exhibiting cytotoxicity.
Given that caffeine is a generic inhibitor, we wanted to
explore treatment with a more specific compound. To
confirm the importance of ATM in this process, the small
molecule ATM inhibitor, KU55933 (which we will refer to
henceforth as ATMin) was utilized. This inhibitor hasbeen shown to specifically inhibit ATM in the low IC50 of
12.9 nM without inhibiting ATR at doses of up to 100 μM
[63]. As Chk2 also phosphorylates BRCA1 in response to
DNA damage [64], a Chk2 inhibitor (Chk2in) was also
tested. TZM-bl cells were transfected with Tat and treated
the next day with vehicle or a titration of ATMin or
Chk2in. Forty eight hours post-treatment the cells were
subjected to both luciferase (Figure 5C) and viability as-
says (Figure 5D). The results showed a dose-dependent
Tat-dependent LTR transcriptional inhibition of up to
~55% in the presence of ATMin but not Chk2in (compare
lanes 6 and 9, panel C), demonstrating ATM kinase speci-
ficity in this inhibitory process. Both inhibitors showed no
cytotoxicity. To further confirm the specific participation
of ATM in Tat-dependent transcription, we performed
ATM selective depletion in Tat-transfected TZM-bl cells.
Results in Figure 5E indicate that upon ATM knockdown,
Tat transactivation of the viral promoter is decreased
by ~45%. As additional controls, ATM levels in these cells
were assayed by qRT-PCR and western blot. ATM expres-
sion was successfully decreased (~40%) at the transcrip-
tional level (compare lanes 3 and 4) and protein levels
were decreased by ~54% (inset panel) as confirmed by
western blot using antibodies against ATM and β-actin as
a loading control.
In order to functionally link the inhibitor study findings
to BRCA1, ChIP assays from Tat-transfected DMSO- and
ATMin-treated TZM-bl cells were performed using anti-
bodies against Histone H3 phosphorylated at serine 10
[pS10-H3 (positive control)], V5 (negative control), and
BRCA1. Results in Figure 5F reveal total BRCA1 (lane 3,
compare white and black bars) occupancy loss (~2-fold)
from the activated HIV-1 LTR with ATMin treatment
when compared to the DMSO control. It is important to
note that we also observed a decrease in pS10-H3 binding
to the LTR following ATMin treatment as well as a de-
crease in RNAP II binding following curcumin treatment
(Figure 4C). These results indicate that these treatments
are affecting more than just BRCA1 binding to the LTR.
As we hypothesize that BRCA1 may be acting as a scaffold
protein, there are likely multiple LTR binding factors that
will be influenced if BRCA1 leaves the LTR. However, we
cannot rule out a global change at the promoter after
treatments that is affecting multiple binding partners.
Taken together, these results suggest that BRCA1 phos-
phorylation plays a role in Tat-dependent transcription as
observed indirectly by the inhibition of upstream BRCA1
activators. Also, they are suggestive of ATM-dependent
BRCA1 phosphorylation requirement for its recruitment
to the HIV-1 LTR in the presence of Tat. Moreover, these
results show that LTR transcription is potently and spe-
cifically inhibited by ATMin. These observations are
correlated with various studies implicating these kinases
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Figure 5 Inhibition of upstream BRCA1 phosphorylation effectors ATR/ATM, decreases Tat-dependent transcription. A. TZM-bl cells were
transfected with pcTat and treated the next day with vehicle (water) and a titration of caffeine (500 μM, 2 mM and 5 mM). Bright-Glo luciferase
assays were performed 48 hours post-treatment. Data was normalized to cells containing Tat and treated with DMSO as baseline for Tat-dependent
LTR activation. B. CellTiter-Glo cell viability assays were performed 48 hours post-treatment. Data was normalized as in panel A. C. TZM-bl cells were
transfected with pcTat and treated the next day with vehicle (DMSO) and a titration of ATM or Chk2 inhibitors (ATMin and Chk2in) at 0.1 μM, 1 μM
and 10 μM. Bright-Glo luciferase assays were performed 48 hours post-treatment. Data was normalized as in panel A. D. CellTiter-Glo cell viability assays
were performed 48 hours post-treatment. Data was normalized as in panel A. E. TZM-bl cells were co-transfected with pcTat or siRNA against
GFP (control) and ATM. Bright-Glo luciferase assays were performed 48 hours post-treatment. Cells containing pcTat and siGFP were used as
baseline value for Tat-dependent LTR activation. ATM depletion was confirmed by qRT-PCR and western blot (right panel and inset). Fold
changes against siGFP were calculated relative to Actin using the ΔΔCt method. F. TZM-bl cells were transfected with pcTat and treated the
next day with DMSO or ATM inhibitor (10 μM) for 48 hours prior to being collected for ChIP analysis. Antibodies used for ChIP were anti-
BRCA1 (10 μg), anti-V5 (10 μg), and anti- pS10-H3 (10 μg). Transfection and treatment assays were performed in triplicate and data represents
averaged data of two independent experiments. Viability assays were performed in triplicate. Error bars show the standard error of two
averaged independent measurements. Double asterisk indicates statistically significant difference p ≤ 0.01.
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theophylline, have been used to inhibit HIV-1 integration
in primary cells [65]. Similarly, HIV-1 IN has been shown
to stimulate an ATM-dependent DNA damage response
and that in the absence of this enzyme, cells are sensitizedto retroviral-induced death [67]. Thus, treatment with
ATMin suppressed viral replication, not only of wild-type,
but drug-resistant HIV-1. Of interest for the present
study, caffeine has been found to prevent pTEF-b dissoci-
ation from its 7SK snRNP inactive complex, illustrating an
Guendel et al. Virology Journal  (2015) 12:40 Page 10 of 14additional mechanism for its inhibition of Tat-dependent
transcription [69].
BRCA1 is present at the HIV-1 LTR in HIV infected T-cells
Finally we aimed to confirm our findings in a T-cell model
of infection. To this end, CEM T-cells were infected with
HIV and BRCA1 occupancy of the LTR assessed by chro-
matin immunoprecipitation. ChIP assays from HIV (NL4-
3) infected CEM T-cells were performed using antibodies
against pS10-H3 (positive control), V5 (negative control),
and BRCA1. Indeed, we observed BRCA1 present at the
LTR in HIV infected T-cells (Figure 6A). Next we exam-
ined if inhibition of BRCA1 phosphorylation through the
use of the ATMin would alter BRCA1 binding to the LTR.
CEM cells were pre-treated with ATMin for 2 hours prior
to infection. ATMin was also added following infection.
Interestingly, no significant difference in BRCA1 bind-
ing to the LTR was observed after ATMin treatment
(Figure 6B). However, a decrease in p-BRCA1 (S1423)
was observed after ATMin treatment, indicating that
there was a shift in the form of BRCA1 bound at the
LTR following ATMin treatment. Collectively these re-
sults indicate that BRCA1 is present at the HIV-1 LTR
in a highly relevant model of HIV infection.
Conclusions
Our data has shown that BRCA1 functions as an enhan-
cer of HIV-1 transcription through gain-of-function and
loss-of-function studies. We have shown that BRCA1 re-
gion aa504-802 associates with Tat, encouraging the ideaA) B




















Figure 6 BRCA1 is present at the HIV-1 LTR in HIV infected T-cells. A. CEM
collected 72 hours post-infection for ChIP analysis. Antibodies used for ChIP we
at S10 (pS10-H3, 5 μg). Quantitative PCR was performed using SYBR Green PCR
pre-treated with DMSO or 10 μM ATM inhibitor (ATMin) for 2 hours. Cells were
post-treating the cells with DMSO or ATMin. Cells were collected 72 hours post-
(10 μg), p-BRCA1 S1423 (10 μg), and anti-V5 (10 μg). Quantitative PCR was perfo
material. Double asterisk indicates statistically significant difference p≤ 0.01.of its participation in Tat-dependent transcription. We
have also used small molecule inhibitors as tools to as-
sess the inhibitory effect of its targets on Tat-dependent
HIV-1 5′ LTR transcription, highlighting the viability of
therapeutic approaches targeting host cell proteins.
BRCA1 phosphorylation in HIV-1 infected cells has pri-
marily been described as a function of ATR as the ef-
fector kinase and as a DNA damage response event [11].
These data explored the effects of ATR/ATM-mediated
phosphorylation of BRCA1 in Tat-dependent transcrip-
tion. More importantly, we have shown for the first time
that BRCA1 is present at the HIV-1 LTR in infection
and that LTR occupancy by the phosphorylated species
is decreased upon treatment with ATMin.
Methods
Cell culture and reagents
TZM-bl cells are engineered HeLa cells that express
CD4, CCR5, and CXCR4 and contain integrated reporter
genes for Firefly luciferase and β-galactosidase under the
control of an HIV-1 long terminal repeat [70,71]. These
cells were cultured to confluency in DMEM supple-
mented with 10% heat-inactivated FBS, 1% L-glutamine,
and 1% streptomycin/penicillin (Gibco/BRL, Gaithersburg,
MD, USA). UWB1.289 cells are derived from ovarian can-
cer in a germ line BRCA1 mutation carrier and lack ex-
pression of BRCA1 [40]. UWB1.289 + BRCA1 cells are
a stable UWB1.289 derivative cell line carrying a
pcDNA3 plasmid coding for wild-type hemagglutinin-
tagged BRCA1 [72]. Cells were purchased from the)





















cells were infected with NL4-3 virus (p24 = 5000 pg/ml) for 4 hours and
re anti-BRCA1 (10 μg), anti-V5 (10 μg), and anti-histone H3-phosphorylated
Master Mix to analyze immunoprecipitated material. B. CEM cells were
then infected with NL4-3 virus (p24 = 5000 pg/ml) for 4 hours, followed by
infection for ChIP analysis. Antibodies used for ChIP were anti-BRCA1
rmed using SYBR Green PCR Master Mix to analyze immunoprecipitated
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USA) and were maintained in 1:1 RPMI 1640/MEGM
(Lonza, Walkersville, MD, USA) supplemented with 3%
fetal bovine serum. CEM is an uninfected T-cell line
and is grown in RPMI media containing 10% FBS, 1%
L-glutamine, and 1% streptomycin/penicillin.
Protein extracts and immunoblotting
Cells were collected, washed once with PBS and pelleted.
For immunoprecipitation, cells were lysed in a buffer
containing Tris–HCl pH 7.5, 120 mM NaCl, 5 mM
EDTA, 0.5% NP-40, 50 mM NaF, 0.2 mM Na3VO4,
1 mM DTT and one tablet complete protease inhibitor
cocktail per 50 ml. Lysis was performed under ice-cold
conditions, incubated on ice for 30 min and spun at 4°C
for 5 min at 14,000 rpm. The protein concentration for
each preparation was determined with by Bradford assay
(Sigma Aldrich, St. Louis, MO, USA). For immunoblot-
ting, lysis buffer consisted of a 1:1 mixture of T-PER re-
agent (Pierce, Rockford, IL, USA) and 2X Tris-glycine
SDS sample buffer (Novex, Life Technologies, Carlsbad,
CA, USA), 33 mM DTT, and protease and phosphatase
inhibitor mixture (1X Halt mixture, Pierce). Cells were
collected directly in lysis buffer and boiled for 10 min.
Cell extracts were resolved by SDS-PAGE on a 4-20%
tris-glycine gel (Invitrogen, Life Technologies). Proteins
were transferred to PVDF membranes by overnight
transfer as described by the manufacturer (Invitrogen,
Life Technologies). Membranes were blocked with PBS
0.1% Tween-20 + 3% BSA. Primary antibodies against
specified proteins were incubated with the membrane in
blocking solution overnight at 4°C. Antibodies against
BRCA1 (sc-642) and BRG1 (sc-10768) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
The ATM (2873) antibody was purchased from Cell Sig-
naling (Beverly, MA, USA). The β-actin antibody
(ab49900) was purchased from Abcam (Boston, MA,
USA). Anti-Flag (F3165) was purchased from Sigma
Aldrich. Membranes were washed twice with PBS + 0.1%
Tween-20 and incubated with HRP-conjugated second-
ary antibody for 1 hour in blocking solution. Presence of
secondary antibody (#32430 and #32460, Pierce) was de-
tected by SuperSignal West Dura Extended Duration
Substrate (Pierce). Luminescence was visualized on a
Molecular Imager ChemiDoc XRS system Bio-Rad sta-
tion (Bio-Rad, Hercules, CA, USA).
Small molecule compounds
The ATM kinase inhibitor (ATMin) 2-morpholin-4-yl-6-
thianthren-1-yl-pyran-4-one (KU55933) and Chk2 kinase
inhibitor (Chk2in) 2-(4-(4-chlorophenoxy)phenyl)-1H-benz-
imidazole-5-carboxamide, were purchased from EMD4
Biosciences (Gibbstown, NJ, USA). Caffeine was purchased
from Sigma Aldrich. Curcumin was purchased from SantaCruz Biotechnology (sc-200509). All inhibitors were pre-
pared in 10 mM stock solution dissolved in DMSO.
Transfections
UWB1.289 and UWB1.289 + BRCA1 cells were seeded
in a 96-well plate and co-transfected with 0.5 μg of
pRL-CMV-luciferase reporter (Renilla), HIV-1 LTR-
luciferase reporter (Firefly), and pcTat101. The Renilla
reporter plasmid was co-transfected to allow correction
for differences in transfection efficiency. For siRNA
transfection, TZM-bl cells were co-transfected in a 96-
well plate with pcTat101 (0.5 μg) and siRNA against
GFP (#P-002048-01-20, Dharmacon, Lafayette, CO,
USA), Hs_BRCA1_15 or Hs_ATM_5 (#SI02664368 and
#SI00299299, Qiagen, Valencia, CA, USA), using Dhar-
maFECT Duo (Dharmacon). For other transcriptional
assays, TZM-bl cells were co-transfected in a 96-well
plate with pcTat101, BRCA1 (wild-type) [73], or BRCA1
4P (S1387A/S1423A/S1457A/ S1524A) mutant [con-
structed by swapping a cDNA fragment harboring the
S1387A and S1423A mutations into the wild-type plasmid
followed by adding additional mutations with sequen-
tial rounds of QuikChange site-directed mutagenesis




3′ and 5′-GAGCTCCTCTTGAGCTGGGT AGTTT
CTATTC-3′(S1524A)]. All cells were collected for lumi-
nescence analysis 48 hours post-transfection, and all
transfections were performed using the Attractene reagent
according to the manufacturer’s instructions (Qiagen) un-
less noted otherwise.
Luciferase and viability assays
Forty-eight hours post-transfection or drug treatment,
luciferase activity of the Firefly luciferase was measured
with Dual-Glo (for assays using Renilla luciferase) or
Bright-Glo Luciferase Assay (Promega, Madison, WI,
USA). Alternatively, CellTiter-Glo (Promega) was used
to measure viability following the manufacturer’s rec-
ommendations. Luminescence was read from a 96-well
plate on an EG&G Berthold luminometer (Berthold
Technologies, Oak Ridge, TN, USA).
GST pull-down and immunoprecipitation
GST tagged proteins were purified as described previ-
ously [59]. Constructs were washed three times with
PBS + 1% Triton X-100, pelleted and resuspended in
PBS + 1% Triton X-100. Bead volume was normalized
between samples by the addition of extra bead slurry
prepared in the same manner for each condition. Whole
cell protein extract from TZM-bl cells that were trans-
fected with Flag-Tat101 for 48 hours was brought up to a
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GST-BRCA1 constructs (1–500, 504–802, 697–1276,
1021–1552, 1501–1861) were rotated at 4°C overnight.
GST-alone and GST-Tat beads were washed once with
TNE150 + 0.1% NP-40 and twice with TNE50 + 0.1% NP-
40. GST-BRCA1 beads were washed once with TNE300 +
0.1% NP-40, once with TNE150 + 0.1% NP-40, and once
with TNE50 + 0.1% NP-40. For IP, 1 mg of whole cell pro-
tein was brought up to a final volume of 500 μl with
TNE50 + 0.1% NP-40 and pre-cleared for 15 min with
50 μl of 30% A/G agarose bead slurry (CalBioChem, La
Jolla, CA). Supernatants were transferred to a new tube
with 10 μg of BRCA1 or normal rabbit IgG antibodies
(Santa Cruz), and the solution was rotated overnight at
4°C. The next day complexes were precipitated with A/
G beads for 90 min. Beads were washed once with
TNE150 + 0.1% NP-40 and twice with TNE50 + 0.1% NP-
40. Cells were collected directly in lysis buffer and
boiled for 10 min. The GST-construct plasmids pDC78
GST-BRCA1 (1–500), pDC80 GST-BRCA1 (1021–
1552), pDC81 GST-BRCA1 (1501–1861), pDC99 GST-
BRCA1 (504–802), pDC208 GST-BRCA1 (697–1276)
were originally a kind gift from Dr. Tanya Paull at the
University of Texas/ICMB [58].
Reporter virus generation and infections
pHCMV-G [74], which expresses the vesicular stomatitis
virus glycoprotein, and pCMVΔR8.2 [75] have been pre-
viously described. pNL-RRE-SA-Luc was generated from
pNL-Luc-RRE-SA [76] and pNL-RRE-SA [77] by inserting
the luciferase gene (Firefly) within the XhoI cloning site
of pNL-RRE-SA. Pseudotyped virions were prepared by
co-transfecting 4×106 HEK-293 T cells with 7.5 μg of
packaging construct pCMVΔR8.2, 10 μg of reporter vector
plasmid pNL-RRE-SA-Luc, and 2.5 μg of the envelope
plasmid pHCMV-G using Lipofectamine 2000 (Invitrogen,
Life Technologies) as recommended by the manufacturer.
Viral particles were harvested 2 days post-transfection, fil-
tered through a 0.45 μm nitrocellulose membrane, and
stored at −80°C. Levels of p24 in the viral supernatant
were measured by ELISA using an in-house ELISA kit.
Twenty-four hours before infection, UWB1.289 and
UWB1.289 + BRCA1 cells were seeded in a 96-well plate
and co-transfected with 0.25 μg of pRL-CMV-luciferase re-
porter (Renilla), and pcDNA or pcTat101. The next day,
the cells were infected in 150 μL of medium containing
virus (p24 = 2,000 pg). Twenty-four hours post-infection
the cells were processed for luciferase readings using the
Dual-Glo system (Promega).
HIV-1 NL4-3 was generated by transfection of plasmid
pNL4-3 into HEK293T cells using lipofectamine 2000
(Invitrogen) as described previously [77]. For infection,
CEM T-cells were incubated with the virus (p24 =
5,000 pg/ml) for 4 hours and then washed twice withmedium to remove unbound viral particles. Infected
cells were resuspended in fresh RPMI supplemented
with 10% heat-inactivated FBS and incubated for
72 hours prior to ChIP assays.Chromatin immunoprecipitation assays
Cells were crosslinked with 1% paraformaldehyde for
10 min and crosslinking was stopped by the addition of
125 mM glycine. Chromatin fragments were prepared
from 5x106 cells per sample. Cells were lysed using SDS
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris–HCl
pH 8.0, one tablet complete protease inhibitor cocktail per
50 ml) on ice for 10 min. Cells were sonicated on ice for 6
bursts of 10 seconds to obtain an average DNA length
of 500 to 1000 bp (Misonix XL 2000, Misonix, NY,
USA). Samples were processed as previously described
[78]. Quantitative PCR was performed using SYBR
Green PCR Master Mix (#4309155, Applied Biosystems,
Foster City, CA) with 5 μl of immunoprecipitated mater-
ial, 0.2 μM of primer [HIV-1 LTR (−69 − +175) Forward
5′-CTGGGCGGGACTGGGGAG-3′ and Reverse 5′-TCA
CACAACAGACGGGCACAC-3′]. The antibodies used
for immunoprecipitation were as follows: total RNAP II
CTD (ab817, Abcam), pS10-H3 (Novex, Life Technolo-
gies), BRCA1 (sc-642, Santa Cruz), p-BRCA1 S1423 (sc-
101647, Santa, Cruz), Sp1 (5931, Cell Signaling), (IgG
(sc-2027, Santa Cruz) or V5 (AbD Serotec, Oxford, UK).qRT-PCR
RNA analysis of BRCA1 and ATM transcripts was per-
formed after selective depletion with the respective siRNA.
Total RNA was isolated from cell pellets using the RNeasy
Kit (Qiagen) according to the manufacturer’s protocol. A
total of 300 ng of RNA was used to generate cDNA with
the High-Capacity RNA-to-cDNA Kit (#4387406, Invi-
trogen, Life Technologies) following manufacturer’s rec-
ommendations. Quantitative PCR was performed with
SYBR Green PCR Master Mix Applied Biosystems). Fold
changes were calculated relative to Actin using the ΔΔCt
method. Primers used are described: BRCA1 Forward
5′-GGCTATCCTCTCAGAGTGACA TTT-3′ and Re-
verse 5′-GCTTTATCAGGTTAT GTTGCATGGT-3′
[79], ATM Forward 5′- CAGGGTAGTTTAGTTGAG
GTTGACAG-3′ and Reverse 5′- CTATACTGGTGGT
CAGTG CCAAAGT-3′ [80].
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